UBS Group’s Aegerion Pharmaceuticals AEGR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2015
Q3
– Sell
-64,000
Closed -$1.21M – 8895
2015
Q2
$1.21M Buy
+64,000
New +$1.39M ﹤0.01% 3409
2014
Q4
– Sell
-100
Closed -$3K – 10706
2014
Q3
$3K Hold
100
– – ﹤0.01% 9884
2014
Q2
$3K Hold
100
– – ﹤0.01% 9927
2014
Q1
$5K Sell
100
-100
-50% -$5.86K ﹤0.01% 9605
2013
Q4
$14K Sell
200
-100
-33% -$7.65K ﹤0.01% 8646
2013
Q3
$26K Sell
300
-6,000
-95% -$509K ﹤0.01% 7742
2013
Q2
$399K Hold
6,300
– – ﹤0.01% 4321

UBS Group's AEGR Position: Q4 2016 in Review

UBS Group sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 3,781 shares — an estimated $11K sold.

UBS Group first reported a position in AEGR in Q2 2013 and held it in 14 quarters. The position peaked at $2.33M in Q3 2013. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.

  • UBS Group reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • UBS Group sold 3,781 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $11K.
  • UBS Group first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
  • UBS Group's Aegerion Pharmaceuticals position peaked at $2.33M in Q3 2013.
  • 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.

Based on UBS Group's 13F filing for Q4 2016, filed 14 Feb 2017.